z-logo
Premium
Identification of essential exported Plasmodium falciparum protein kinases in malaria‐infected red blood cells
Author(s) -
Siddiqui Ghizal,
Proellochs Nicholas I.,
Cooke Brian M.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16219
Subject(s) - plasmodium falciparum , biology , malaria , parasite hosting , kinase , plasmodium (life cycle) , immunology , microbiology and biotechnology , organelle , virology , computer science , world wide web
Summary FIKK kinases in the human malaria parasite Plasmodium falciparum are attractive targets for new anti‐malaria drugs, as they have no orthologues in humans and have been linked to disease severity. Six FIKKs are known to be exported into red blood cells (RBCs) where they mediate dramatic structural and functional changes to RBCs that are central to pathogenesis. Eleven members of this family, which are predicted to be exported into infected RBCs (iRBCs), remain uncharacterised. Using a targeted gene‐knockout approach, we have characterised these FIKKs and discovered that five are essential for parasite survival. Three of these five FIKKs (FIKK9.1, FIKK10.1, FIKK10.2) were exported from the parasite into iRBCs and for two of these (FIKK9.1 and FIKK10.1), export was via Maurer’s clefts (parasite‐derived structures involved in protein trafficking and pathognomonic of falciparum malaria). Of the remaining two essential kinases, FIKK3 was associated with rhoptries (specialised protein secretory organelles in the parasite) and FIKK9.5 was localised in the parasite nucleus. The diverse localisation and essentiality of these FIKKs demonstrate that they play different but essential roles in the survival of P. falciparum in RBCs and therefore are attractive new drug targets for the prevention or treatment of falciparum malaria.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here